Int J Oral Maxillofac Implants. 2020 May/Jun;35(3):485-494. doi: 10.11607/jomi.7995.
The aim of this systematic review was to estimate if an antibiotic prophylaxis regimen reduces implant failure and postoperative infection in healthy patients who are going to receive dental implants.
An electronic database search (MEDLINE/PubMed, Scopus, Web of Science, Cochrane Library) until June 30, 2019, for randomized controlled trials (RCTs) was performed. The Cochrane Handbook for Systematic Reviews of Interventions to assess the risk of bias in individual studies was used. Patient- and implant-level data were extracted for the analyzed outcomes. The risk ratio (RR) and the 95% confidence interval were calculated as meta-analytic effects. A fixed- or a random-effect model was employed on the basis of the presence/absence of heterogeneity (I > 50%). Differences between groups were analyzed using the inverse of variance test. The Higgins Index and chi-square test were used to assess the studies' heterogeneity. Additionally, in order to evaluate the power of evidence and to adjust the meta-analytic findings for type 1 and 2 errors, a trial sequential analysis (TSA) was performed.
Nine studies including 1,984 patients and 3,588 implants were selected. Eight hundred eighty-five patients (1,617 implants) received no antibiotics or a placebo therapy before the implant surgery; 1,971 implants (1,099 patients) were treated with an antibiotic therapy. The meta-analysis at the patient level showed a statistically significant reduction in the rate of early implant failure associated with the use of antibiotics (I = 0%) (RR = 0.32 [0.20, 0.51], P > .001). Similar results were obtained after pooling the implant-level data with the fixed-effect model (RR = 0.33 [0.22, 0.51], P > .001). Such results were also confirmed by the TSA after adjusting for type 1 and 2 errors.
The results of this systematic review with meta-analysis indicate that an antibiotic prophylaxis prevents early implant failures in the case of healthy patients. No information can be provided on peri-implant infections.
本系统评价的目的是评估在接受牙种植体的健康患者中,抗生素预防方案是否会降低种植体失败和术后感染的发生率。
对截至 2019 年 6 月 30 日的 MEDLINE/PubMed、Scopus、Web of Science、Cochrane 图书馆的电子数据库进行了检索,以查找随机对照试验(RCT)。使用 Cochrane 系统评价干预措施手册评估个体研究的偏倚风险。提取分析结局的患者和种植体水平数据。计算风险比(RR)和 95%置信区间作为荟萃分析效应。基于是否存在异质性(I > 50%),采用固定效应或随机效应模型。采用方差倒数检验分析组间差异。采用 Higgins 指数和卡方检验评估研究的异质性。此外,为了评估证据的效力并调整荟萃分析结果以纠正 1 型和 2 型错误,进行了试验序贯分析(TSA)。
共纳入 9 项研究,涉及 1984 名患者和 3588 枚种植体。885 名患者(1617 枚种植体)在种植术前未接受抗生素或安慰剂治疗;1971 枚种植体(1099 名患者)接受抗生素治疗。患者水平的荟萃分析显示,使用抗生素可显著降低早期种植体失败率(I = 0%)(RR = 0.32 [0.20,0.51],P >.001)。使用固定效应模型汇总种植体水平数据也得到了类似的结果(RR = 0.33 [0.22,0.51],P >.001)。通过调整 1 型和 2 型错误,TSA 也证实了这一结果。
本系统评价和荟萃分析的结果表明,在健康患者中,抗生素预防可预防早期种植体失败。但对于种植体周围感染,我们无法提供相关信息。